NCT07215910
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 152 → 177 locations
- Notable Eligibility criteria expanded, about 41 words
- Trial sites expanded: 121 → 152 locations
- Secondary endpoints: details revised at 16 of 16 entries
- Study description revised
- Minor Trial sites expanded: 97 → 121 locations
- Start date changed from estimate of Jul 20, 2026 to Jun 24, 2026
- Minor Trial sites expanded: 82 → 97 locationsv4
- Minor Trial sites expanded: 75 → 82 locationsv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Oct 20, 2025 to Jul 20, 2026
- Study sites: 0 to 75
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (16)
Show 11 moreShow less
Arms and interventions
Patients receive IMRT/VMAT or PBS or IMPT QD on Monday-Friday for 33 fractions. Starting 4 weeks after radiotherapy, patients receive temozolomide PO QD on days 1-5 and placebo PO QD on days 1-28 of each cycle. Cycles of combination treatment repeat every 28 days for up to 12 months and placebo alone repeats every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the study.
Patients receive IMRT/VMAT or PBS or IMPT QD on Monday-Friday for 33 fractions. Starting 4 weeks after radiotherapy, patients receive temozolomide PO QD on days 1-5 and vorasidenib PO QD on days 1-28 of each cycle. Cycles of combination treatment repeat every 28 days for up to 12 months and vorasidenib alone repeats every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI throughout the study.
Radiation: Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning
Procedures: Intensity-Modulated Proton Therapy, Biospecimen Collection, Magnetic Resonance Imaging
Drugs: Temozolomide, Vorasidenib, Placebo Administration
Other: Questionnaire Administration
Sites
177 sites in 1 country